Executives at Irvine-based Allergan Inc. and a rival maker of a wrinkle-removing drug might have a few worry lines popping up on their foreheads on Monday.
The Food and Drug Administration has set a Monday deadline to review an application for Reloxin, a wrinkle-fighting drug being developed by Medicis Pharmaceutical Corp. of Scottsdale.
Reloxin is the closest competitor to Allergan’s blockbuster Botox, which has had the wrinkle-remover drug market to itself for years.
Like Botox, Reloxin is made from a purified form of a toxin related to botulism, a type of food poisoning.
Medicis has said it expects quick approval of Reloxin. Most analysts expect it to be sold in the second half of the year.
Allergan isn’t waiting.
For more on this story, read the April 13 issue of the Business Journal.
